| 3.49 0.45 (14.8%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.07 |
1-year : | 4.76 |
| Resists | First : | 3.49 |
Second : | 4.07 |
| Pivot price | 2.96 |
|||
| Supports | First : | 2.69 |
Second : | 2.21 |
| MAs | MA(5) : | 3.11 |
MA(20) : | 2.86 |
| MA(100) : | 2.67 |
MA(250) : | 2.44 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.8 |
D(3) : | 82.8 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 4.38 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADAG ] has closed above the upper band by 21.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 15.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.49 - 3.51 | 3.51 - 3.53 |
| Low: | 3.05 - 3.07 | 3.07 - 3.09 |
| Close: | 3.46 - 3.49 | 3.49 - 3.52 |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Wed, 11 Sep 2024
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Thu, 29 Aug 2024
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Thu, 29 Aug 2024
Adagene to Participate in Investor Conferences in September - StockTitan
Wed, 28 Aug 2024
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - MSN
Fri, 12 Jul 2024
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Wed, 02 Mar 2022
Adagene Announces SAFEbody® Multi-Target Collaboration with - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.316e+007 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.613e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 534.8 % |
| Return on Equity (ttm) | -19.6 % |
| Qtrly Rev. Growth | 815750 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -70.31 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.77 |
| Dividend | 0 |
| Forward Dividend | 13010 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|